Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer
Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST
TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases